SueSisley, PhD
psychiatrist, researcher
- Assistant Professor, Clinical Faculty – University of Arizona Collegeof Medicine, Tucson, Arizona
- Arizona Telemedicine Program, Assistant Director of
- Interprofessional Education, Phoenix, AZ
- Principal Investigator, FDA-Approved Investigation of the Safety and Efficacy of Medical Marijuana in Veterans with Chronic, Treatment-Resistant PTSD
Dr. Sue Sisley MD is an Arizona-based physician practicing Internal Medicine and Psychiatry.
She works as Medical Director for medical cannabis license holders in 11 different states/territories from Hawaii to Puerto Rico to New York.
Sue serves as Site Principal Investigator for the only FDA-approved randomized controlled trial in the world examining safety/efficacy of whole plant marijuana in combat veterans with treatment-resistant post traumatic stress disorder PTSD. Dr. Sisley is on faculty at Colorado State University PUEBLO campus, recruited for core planning team to organize the CSUP "ICR Institute of Cannabis Research" in Pueblo, Colorado. Dr. Sisley has been a Member of Nevada ILAC Medical Cannabis Commission for the past two years outlining regulations for laboratory testing including limits on pesticides, residual solvents and other guidelines that are currently being used as a model for other states medical cannabis laws. She also serves on the Steering Committee for Thomas Jefferson University Lambert Cannabis .
Lectures and workshops on our seminars
| 2015 | The use of medical marijuana to treat patients with treatment-resistant Post-Traumatic Stress Disorder (PTSD) | Abstract |
|
The use of medical marijuana to treat patients with treatment-resistant Post-Traumatic Stress Disorder (PTSD) is supported by a number of sources, including research in lab animals, fMRI imaging in humans, and anecdotal reports from countless health practitioners and patients. Additionally, clinical research in Israel evaluating medical marijuana as treatment for PTSD has been promising. This study will test four strains of smoked marijuana, each containing different concentrations of active cannabinoids, in two three-week stages, as a pharmacological agent to manage PTSD symptoms among 80 American war veterans. This study is a collaboration between me and researchers from Johns Hopkins University, University of Colorado, and University of Pennsylvania. This will be the first randomized controlled crossover clinical trial in the United States testing the therapeutic potential of marijuana for PTSD. The primary measured outcome will be the Clinician Administered PTSD Scale (CAPS-5), alongside extensive secondary outcomes including sleep patterns, depression, withdrawal symptoms, metabolic and inflammation panels, and self-reporting by the patients. |
||
| 2015 | The use of medical marijuana to treat patients with treatment-resistant Post-Traumatic Stress Disorder (PTSD) | info |
|
At the workshop we will learn about:
|
||
| 2017 | Researching Medical Cannabis: Navigating Barriers To Efficacy Research | Abstract |
|
Lecture will discuss the barriers to Cannabis efficacy research and myriad ways US government has systematically impeded this work. We will use our recent battle to implement the veterans research as prime example of this research blockade trying to use medical marijuana to treat patients with treatment-resistant Post-Traumatic Stress Disorder (PTSD). This FDA approved Phase 2 cannabis clinical trial is supported by a number of sources, including research in lab animals, fMRI imaging in humans, and anecdotal reports from countless health practitioners and patients. Additionally, clinical research in Israel evaluating medical marijuana as treatment for PTSD has been promising. MAPS' study will test four strains of smoked marijuana, each containing different concentrations of active cannabinoids, in two three-week stages, as a pharmacological agent to manage PTSD symptoms among 76 American war veterans. This study is a collaboration between Dr. Sue Sisley, and researchers from Johns Hopkins University, University of Colorado, and University of Pennsylvania. This will be the first randomized controlled crossover clinical trial in the United States testing the therapeutic potential of marijuana for PTSD. The primary measured outcome will be the Clinician Administered PTSD Scale (CAPS-5), alongside extensive secondary outcomes including sleep patterns, depression, withdrawal symptoms, metabolic and inflammation panels, and self-reporting by the patients. Four Learning objectives:
|
||
| 2017 | Researching Medical Cannabis: Navigating Barriers To Efficacy Research | Workshop |
| 2019 | Research barriers in the science of cannabis | Abstract |
|
Discuss strategies US government has employed to systematically impede cannabis efficacy research & challenges trying to push natural cannabis flower through the entire FDA drug development process.
|
||
